Cognition Therapeutics, Inc. (CGTX)
NASDAQ: CGTX · Real-Time Price · USD
1.050
-0.030 (-2.78%)
At close: Aug 10, 2026, 4:00 PM EDT
1.059
+0.009 (0.88%)
After-hours: Aug 10, 2026, 7:36 PM EDT
Cognition Therapeutics Employees
Cognition Therapeutics had 14 employees as of December 31, 2025. The number of employees decreased by 14 or -50.00% compared to the previous year.
Employees
14
Change (1Y)
-14
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$1,198,214
Market Cap
93.97M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 14 | -14 | -50.00% | 14 | 0 |
| Dec 31, 2024 | 28 | 0 | - | 25 | 3 |
| Dec 31, 2023 | 28 | 3 | 12.00% | 25 | 3 |
| Dec 31, 2022 | 25 | 4 | 19.05% | 22 | 3 |
| Dec 31, 2021 | 21 | 1 | 5.00% | 19 | 2 |
| Sep 30, 2021 | 18 | -2 | -10.00% | 15 | 3 |
| Jun 30, 2021 | 22 | - | - | 18 | 4 |
| Mar 31, 2021 | 22 | - | - | 20 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortress Biotech | 78 |
| Verrica Pharmaceuticals | 76 |
| PolyPid | 75 |
| ImmuCell | 73 |
| Biomea Fusion | 37 |
| Oncolytics Biotech | 29 |
| Rallybio | 9 |
| Aldeyra Therapeutics | 7 |
CGTX News
- 4 days ago - Cognition Therapeutics reports Q2 EPS (4c), consensus (6c) - TheFly
- 4 days ago - Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update - GlobeNewsWire
- 4 days ago - Cognition Therapeutics Earnings release: Q2 2026 - Filings
- 4 days ago - Cognition Therapeutics Quarterly report: Q2 2026 - Filings
- 9 days ago - Cognition Therapeutics Slides: Investor presentation - Filings
- 4 weeks ago - Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit - GlobeNewsWire
- 6 weeks ago - Cognition Therapeutics gets FDA feedback on zervimesine study - TheFly
- 6 weeks ago - Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes - GlobeNewsWire